Macular Edema
Conditions
Brief summary
Retrospective cases series is a non-randomized, open-label, single-center investigation (Retina Clinic, São Paulo, Brazil) of patients diagnosed with macular edema secondary to diabetic retinopathy (DME) and retinal vein occlusions who underwent to simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and implant of dexamethasone 0.7mg.
Detailed description
This retrospective cases series is a non-randomized, open-label, single-center investigation (Retina Clinic, São Paulo, Brazil) approved by the Institutional Review Board of Hospital Oftalmológico de Sorocaba/SP, and adhered to the tenets of the Declaration of Helsinki. Were included patients older than 18 years, treated between April 2014 and July 2015, diagnosed with macular edema secondary to diabetic retinopathy (DME) and retinal vein occlusions who underwent to simultaneous treatment with intravitreal injection of bevacizumab 1.25mg (Avastin; Genentech, South San Francisco, CA) and intravitreal implant of dexamethasone 0.7mg (Ozurdex; Allergan, Inc, Irvine, CA).
Interventions
DRUGsimultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.
Sponsors
Retina Clinic, Sao Paulo, Brazil
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* central macular thickness \> 300 µm on optical coherence tomography (OCT) * macular edema secondary to diabetic retinopathy (DME) and retinal vein occlusions
Exclusion criteria
* intravitreal anti-VEGF within 6 weeks * treatment with laser or intravitreal corticosteroids within 3 months of study entry.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in BCVA | 6 months |
Countries
Brazil
Outcome results
None listed